ImmusanT recently expanded its senior staff, bringing on Daiichi Sankyo’s senior VP for internal medicine, Ken Truitt, as its chief medical officer.
Researchers at American University believe they’ve uncovered a signaling pathway that prompts beige cells to burn energy.
For children diagnosed with rare diseases, traditional drug development timelines are not good enough. Collaborative partnerships are imperative to accelerate…
Sanofi is trumpeting new data for a hemophilia A drug developed by Bioverativ that it says could transform treatment of the bleeding disorder.
Galecto Biotech hired Richard Marshall, head of fibrosis discovery at GlaxoSmithKline, to be CMO as it moves into late-phase trials of its IPF drug.
The positive readout further burnishes the prospects of the antibiotic, which is set to go before the FDA later this year.
A phase 2 trial of Allergy Therapeutics’ grass pollen candidate met its primary endpoint of showing a dose-response relationship.
A treatment that curbs an immune response in the brain could ward off poststroke inflammation.
The funding will advance Rain's hypoxia-activated prodrug in patients with non-small cell lung cancer for whom there are no treatments.
Johnson & Johnson unit Janssen joins the Alzheimer's failure club after deciding to stop trials of its BACE inhibitor atabacestat.
The CEA-CD3 bispecific T-cell engager was pitched as a treatment for colorectal cancer but looks to have failed in early-phase trials.